The honest answers to your GLP-1 questions, all in one place.

The GLP-1 news worth knowing from the past week — ranked by what actually matters, so you can catch up in a minute.

1. 1
   Regulatory

   EU Regulator Recommends Approval of Eli Lilly's Oral Obesity Pill Foundayo

   The European Medicines Agency's human medicines committee (CHMP) recommended EU approval of Eli Lilly's oral GLP-1 pill Foundayo (orforglipron) for weight management and type 2 diabetes, based on trial data from more than 4,740 adults showing 5 to 11 percent weight loss across doses at 72 weeks versus roughly 2 to 2.5 percent on placebo. The European Commission still must issue a final decision, typically within a few weeks of a CHMP opinion; Foundayo would become the second oral GLP-1 pill available in the EU after Novo Nordisk's oral Wegovy, which was approved for weight management in July.

   PharmExecRead the original at PharmExec (opens in a new tab)
2. 2
   Clinical

   Eli Lilly's Zepbound-Eloralintide Combination Drives Greater Weight Loss Than Zepbound Alone in Mid-Stage Trial

   A Lilly Phase 2 trial pairing Zepbound (tirzepatide) with the amylin-targeting candidate eloralintide produced an average of 23.3% body weight loss over roughly 11 months at the highest combination dose, versus 14.8% for Zepbound alone. STAT noted high rates of trial discontinuation in the combination arms, which may raise tolerability questions even as the efficacy data looked strong.

   STAT NewsRead the original at STAT News (opens in a new tab)
3. 3
   Clinical

   Lilly's Experimental EloraTZP Combination Produces Up to 23.3% Weight Loss in Phase 2b Trial

   A Phase 2b trial of EloraTZP, Eli Lilly's investigational combination of the amylin analog eloralintide and tirzepatide, found the highest-dose combination produced average weight loss of 23.3% at 48 weeks in adults with obesity and type 2 diabetes, compared with 14.8% for tirzepatide alone. The 367-person trial also showed larger blood-sugar reductions with the combination, though more participants discontinued the combination than tirzepatide alone due to side effects.

   Pharmacy TimesRead the original at Pharmacy Times (opens in a new tab)
4. 4
   Research

   Weight-loss drugs show signs of slowing biological aging, say drugmakers

   Novo Nordisk and Eli Lilly presented preliminary data at a Boston aging-research conference suggesting GLP-1 drugs may lower molecular measures of biological age by roughly two to three years in trial participants. Novo's analysis drew on blood samples from more than 10,000 people across five semaglutide trials, while Lilly's smaller tirzepatide analysis used epigenetic clocks; neither has been peer-reviewed and the effect has so far been shown mainly in overweight or diabetic patients rather than healthy people.

   MIT Technology ReviewRead the original at MIT Technology Review (opens in a new tab)
5. 5
   Market

   Roche Signs Deal Worth Up to $1.16 Billion With China's Rona Therapeutics for Obesity Drug Candidate

   Roche has licensed an ALK7-targeting RNAi obesity candidate from China's Rona Therapeutics, in a deal announced October 13 worth up to $1.16 billion before royalties: about $100 million in upfront and near-term payments plus up to $1.06 billion in milestones. The experimental therapy aims to silence the ALK7 receptor to reduce visceral and other ectopic fat while preserving lean mass, which Rona says could complement existing incretin-based drugs like semaglutide and tirzepatide; no clinical data has been disclosed yet for the unnamed candidate. The deal follows a similar May 2026 GSK-SiranBio ALK7 licensing agreement and reflects Roche's stated goal of becoming a top-three player in the obesity drug market.

   Fierce BiotechRead the original at Fierce Biotech (opens in a new tab)